Egetis Therapeutics AB (LTS:0ABW) Total Stockholders Equity: kr481.30 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABW Egetis Therapeutics AB LTS:0ABW
51 GF Score
Price kr7.72
GF Value kr5.31
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Total Stockholders Equity?

Egetis Therapeutics AB LTS:0ABW -3.62% 51 Total Stockholders Equity is kr481.30 Mil as of Jun. 2026. GuruFocus rates LTS:0ABW with a GF Score™ of 51/100 and a GF Value™ of kr5.31 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Egetis Therapeutics AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr481.30 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Egetis Therapeutics AB's Book Value per Share for the quarter that ended in Jun. 2026 was kr1.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Egetis Therapeutics AB's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.13.

Egetis Therapeutics AB  (LTS:0ABW) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Egetis Therapeutics AB's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(481.3-0)/464.947
=1.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Egetis Therapeutics AB's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(64.7 + 0) / 481.3
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Total Stockholders Equity Related Terms

Egetis Therapeutics AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Total Stockholders Equity Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 527.00 506.20 545.60 492.80 338.60

Egetis Therapeutics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.00 277.40 338.60 248.40 481.30
LTS:0ABW
51GF Score
Egetis Therapeutics AB LTS:0ABW
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr481.30 Mil mean?
Egetis Therapeutics AB (LTS:0ABW) has a Total Stockholders Equity of kr481.30 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Total Stockholders Equity too high?
Egetis Therapeutics AB's current Total Stockholders Equity is kr481.30 Mil. Overall, Egetis Therapeutics AB has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Total Stockholders Equity compare to VRTX and REGN?
Egetis Therapeutics AB's Total Stockholders Equity of kr481.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Total Stockholders Equity is kr481.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.31, compared to a current price of kr7.72 — trading 45.4% above its estimated fair value. The current Total Stockholders Equity is kr481.30 Mil. Egetis Therapeutics AB's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Total Stockholders Equity is kr481.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr7.72 is trading 45.4% above its estimated GF Value™ of kr5.31. GuruFocus considers Egetis Therapeutics AB to be Significantly Overvalued.

Key valuation signals for LTS:0ABW:

  • Total Stockholders Equity: kr481.30 Mil
  • GF Value™: kr5.31 vs. price of kr7.72 (45.4% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
51GF Score

Get the complete analysis for LTS:0ABW

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.72
Price
kr5.31
GF Value